References
- CourtneyCFarrellDGrayRAD2000 Collaborative Group2004Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trialLancet36321051515220031
- [AHA and NAC] Alzheimer’s Association and the National Alliance for Caregiving1999Who cares? Families caring for persons with Alzheimer’s diseaseWashington, DC
- [APA] American Psychiatric Association1994Committee on nomenclature and statisticsDiagnostic and statistican manual of mental disordersRevised Fourth EditionWashington DCAPA
- AndersenCKLauridsenJAndersenK2003Cost of dementia: impact of disease progression estimated in longitudinal dataScand J Public Health311192512745762
- BaumgartenMBattistaRInfante-RivardC1997Use of physician services among family caregivers of elderly persons with dementiaJ Clin Epidemiol501265729393382
- BeachDL1997Family caregiving: the positive impact on adolescent relationshipsGerontologist3723389127979
- BeckerR1991Therapy of cognitive deficit in Alzheimer’s disease: The cholinergic systemBeckerRGiacobiniECholinergic basis for Alzheimer therapyBoston, MABirhauser
- BeeriMSWernerPDavidsonM2002The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patientsInt J Geriatr Psychiatry17403811994927
- BirksJHarveyR2003Donepezil for dementia due to Alzheimer’s diseaseCochrane Database Syst Rev3CD00119012917900
- BlesaR2000Galantamine: therapeutic effects beyond cognitionDement Geriatr Cogn Disord11Suppl 1283410971049
- BrookmeyerRCorradaMMCurrieroFC2002Survival following a diagnosis of Alzheimer diseaseArch Neurol591764712433264
- BrookmeyerRGraySKawasC1998Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onsetAm J Public Health881337429736873
- BucksRSAshworthDLWilcockGK1996Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living ScaleAge Ageing25113208670538
- BurnsA2000The burden of Alzheimer’s diseaseInt J Neuropsychopharmacol331811343622
- CallahanCMHendrieHCTierneyWM1995Documentation and evaluation of cognitive impairment in elderly primary care patientsAnn Intern Med12242297856990
- [CSHAWG] Canadian Study of Health and Aging Working Group1994Canadian study of health and aging: study methods and prevalence of dementiaCMAJ1508999138131123
- CaroJJGetsiosDMigliaccio-WalleK2001Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time careNeurology579647111571318
- CaroJJSalasMWardA2002Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in the NetherlandsDement Geriatr Cogn Disord1484912145455
- CarrDBGoateAPhilD1997Current concepts in the pathogenesis of Alzheimer’s diseaseAm J Med1033S10S9344401
- [CDC and NCCDPHP] Centers for Disease Control and National Center for Chronic Disease Prevention and Health Promotion2000Unrealized prevention opportunities: reducing the health and economic burden of chronic illnessAtlanta, GA, USAUS Department of Health and Human Services, Centers for Disease Control and Prevention
- Corey-BloomJAnandJVeachJ1998A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Geriatr Psychopharmacol15565
- CummingsJLColeG2002Alzheimer diseaseJAMA2872335811988038
- CummingsJLSchneiderLTariotPN2004Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s diseaseAm J Psychiatry161532814992980
- DeJongROsterlundOWRoyGW1989Measurement of quality-of-life changes in patients with Alzheimer’s diseaseClin Ther11545542776169
- DoodyRSStevensJCBeckC2001Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology5611546611342679
- DunkinJJAnderson-HanleyC1998Dementia caregiver burden: a review of the literature and guidelines for assessment and interventionNeurology51Suppl 1S5360discussion S65–79674763
- EngelhartMJGeerlingsMIRuitenbergA2002Dietary intake of antioxidants and risk of Alzheimer diseaseJAMA2873223912076218
- ErnstRHayJ1994The US economic and social costs of Alzheimer’s disease revisitedAm J Public Health84126148059882
- ErnstRLHayJWFennC1997Cognitive function and the costs of Alzheimer disease. An exploratory studyArch Neurol54687939193203
- EttnerSL1995The impact of “parent care” on female labor supply decisionsDemography3263807774731
- EvansDA1990Estimated prevalence of Alzheimer’s disease in the United StatesMilbank Q68267892233632
- FarlowMRAnandRMessinaJJr2000A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s diseaseEur Neurol442364111096224
- FarlowMRHakeAMessinaJ2001Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progressionArch Neurol584172211255445
- FarrerLACupplesLAHainesJL1997Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis ConsortiumJAMA2781349569343467
- FeldmanHGauthierSHeckerJ2003Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burdenJ Am Geriatr Soc517374412757558
- FeldmanHGauthierSHeckerJ2004Economic evaluation of donepezil in moderate to severe Alzheimer diseaseNeurology636445015326236
- FeldmanHGauthierSHeckerJ2001A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology576132011524468
- FillitHM1999Improving the quality of managed care for patients with mild to moderate Alzheimer’s diseaseDrug Benefit Trends1611
- FillitHMGuttermanEMLewisB1999Donepezil use in managed Medicare: effect on health care costs and utilizationClin Ther2121738510645761
- FillitHM2000The pharmacoeconomics of Alzheimer’s diseaseAm J Manag Care622 SupplS113944discussion S1145–811142178
- FillitHMGuttermanEMBrooksRL2000Impact of donepezil on caregiving burden for patients with Alzheimer’s diseaseInt Psychogeriatr1238940111081959
- FrancoisCSintonenHSulkavaR2004Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: A Markov Model in FinlandClin Drug Invest2437384
- FratiglioniLDe RonchiDAguero-TorresH1999Worldwide prevalence and incidence of dementiaDrugs Aging153657510600044
- GalaskoDRSchmittFAJinS2000Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer’s diseaseNeurobiol Aging21Suppl 1S168
- GaoSHendrieHCHallKS1998The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysisArch Gen Psychiatry55809159736007
- GarfieldFBGetsiosDCaroJJ2002Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in SwedenPharmacoeconomics206293712141890
- GauthierSFeldmanHHeckerJ2002Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s diseaseInt Psychogeriatr1438940412670060
- GetsiosDCaroJJCaroG2001Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in CanadaNeurology57972811571319
- GuttermanEMMarkowitzJSLewisB1999Cost of Alzheimer’s disease and related dementia in managed-MedicareJ Am Geriatr Soc4710657110484247
- HauberABGnanasakthyAMauskopfJA2000Savings in the cost of caring for patients with Alzheimer’s disease in Canada: an analysis of treatment with rivastigmineClin Ther224395110823365
- HauberABGnanasakthyASnyderEH2000Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigminePharmacoeconomics173516010947490
- HebertLEScherrPABeckettLA1995Age-specific incidence of Alzheimer’s disease in a community populationJAMA273135497715060
- HebertLEScherrPABieniasJL2003Alzheimer disease in the US population: prevalence estimates using the 2000 censusArch Neurol6011192212925369
- HepburnKWLewisMShermanCW2003The savvy caregiver program: developing and testing a transportable dementia family caregiver training programGerontologist439081514704391
- HillJWFuttermanRMasteyV2002The effect of donepezil therapy on health costs in a Medicare managed care planManag Care Interface15637011925682
- HuangLFCartwrightWSHuTW1988The economic cost of senile dementia in the United States, 1985Public Health Reports103373124195
- HuxMJO’BrienBJIskedjianM1998Relation between severity of Alzheimer’s disease and costs of caringCMAJ159457659757169
- JonesRWMcCronePGuilhaumeC2004Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspectiveDrugs Aging216072015260515
- KauferDISadikK2002Galantamine reduces caregiver time spent providing assistance to individuals with mild-to-moderate Alzheimer’s diseaseAm J Geriatr Psychiatry10suppl 1845
- KoppelR2002Alzheimer’s disease: the costs to U.S. businesses in 2002Philadelphia, PA, USAAlzheimer’s Association
- LangaKMChernewMEKabetoMU2001National estimates of the quantity and cost of informal caregiving for the elderly with dementiaJ Gen Intern Med16770811722692
- LeonJNeumannP1998Alzheimer’s disease care: costs and potential savingsHealth Affairs17206169916370
- LuchsingerJATangMXSheaS2003Antioxidant vitamin intake and risk of Alzheimer diseaseArch Neurol60203812580704
- MarcussonJBullockRGauthierS2003Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer diseaseAlzheimer Dis Assoc Disord17Suppl 3S869114512822
- MaxW1996The cost of Alzheimer’s disease. Will drug treatment ease the burden?Pharmacoeconomics951010172695
- MaxWWebberPFoxP1995Alzheimer’s disease: The unpaid burden of caringJ Aging Health71799910172777
- McKhannGDrachmanDFolsteinM1984Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology34939446610841
- MeekPMcKeithanKSchumockG1998Economic considerations in Alzheimer’s diseasePharmacotherapy18(2 Pt 2)6873discussion 79–829543467
- Migliaccio-WalleKGetsiosDCaroJJ2003Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer’s disease in the United StatesClin Ther2518062512860500
- MittelmanMSFerrisSHShulmanE1996A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trialJAMA2761725318940320
- MooreMJZhuCWClippEC2001Informal costs of dementia care: estimates from the National Longitudinal Caregiver StudyJ Gerontol B Psychol Sci Soc Sci56S2192811445614
- MorrisJCHeymanAMohsRC1989The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s diseaseNeurology391159652771064
- MurmanDLChenQPowellMC2002The incremental direct costs associated with behavioral symptoms in ADNeurology591721912473759
- MurmanDLKuoSBPowellMC2003The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodiesNeurology61944914557565
- NeumannPJHermannRCKuntzKM1999Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s diseaseNeurology5211384510214734
- O’BrienBJGoereeRHuxM1999Economic evaluation of donepezil for the treatment of Alzheimer’s disease in CanadaJ Am Geriatr Soc47570810323651
- ParnettiLSeninUMecocciP1997Cognitive enhancement therapy for Alzheimer’s disease. The way forwardDrugs53752689129864
- RaskindMAPeskindERWesselT2000Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study GroupNeurology542261810881250
- ReisbergBDoodyRStofflerA2003Memantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med34813334112672860
- RiceDPFoxPJMaxW1993The economic burden of Alzheimer’s disease careHealth Aff (Millwood)12164768375811
- RichardsSSHendrieHC1999Diagnosis, management, and treatment of Alzheimer disease: a guide for the internistArch Intern Med1597899810219924
- RiveBVercellettoMDamierFD2004Memantine enhances autonomy in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry194586415156547
- RogersRLMeyerJSMortelKF1990After reaching retirement age physical activity sustains cerebral perfusion and cognitionJ Am Geriatr Soc3812382299115
- RoslerMAnandRCicin-SainA1999Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trialBMJ318633810066203
- SanoMErnestoCThomasRG1997A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative StudyN Engl J Med3361216229110909
- SanoMWilcockGvan BaelenB2003The effects of galantamine treatment on caregiver time in Alzheimer’s diseaseInt J Geriatr Psychiatry189425014533127
- SmallGWDonohueJABrooksRL1998An economic evaluation of donepezil in the treatment of Alzheimer’s diseaseClin Ther20838509737841
- SmallGWMcDonnellDDBrooksRL2002The impact of symptom severity on the cost of Alzheimer’s diseaseJ Am Geriatr Soc50321712028215
- SmallGWRabinsPVBarryPP1997Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics SocietyJAMA2781363719343469
- SouetreEThwaitesRMYeardleyHL1999Economic impact of Alzheimer’s disease in the United Kingdom: Cost of care and disease severity for non-institutionalised patients with Alzheimer’s diseaseBr J Psychiatry17451510211151
- SternYTangMXAlbertMS1997Predicting time to nursing home care and death in individuals with Alzheimer diseaseJAMA277806129052710
- StewartAPhillipsRDempseyG1998Pharmacotherapy, for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezilInt J Geriatr Psychiatry13445539695032
- StommelMCollinsCEGivenBA1994The costs of family contributions to the care of persons with dementiaGerontologist341992058005492
- StoneRCafferataGSanglJ1987Caregivers of the frail elderly: a national profileGerontologist27616262960595
- SzafranRF2002Age-adjusted labor force participation rates, 1960–2045Monthly Labor Review1252538
- TariotPNFarlowMRGrossbergGT2004Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trialJAMA2913172414734594
- TariotPNSolomonPRMorrisJC2000A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study GroupNeurology5422697610881251
- TaylorDSloanF2000How much do persons with Alzheimer’s disease cost MedicareJ Am Geriatr Soc486394210855599
- TeriLLogsdonRYesavageJ1997Measuring behavior, mood, and psychiatric symptoms in Alzheimer diseaseAlzheimer Dis Assoc Disord11Suppl 65099437448
- TeriLTruaxP1994Assessment of depression in dementia patients: association of caregiver mood with depression ratingsGerontologist3423148005496
- WardACaroJJGetsiosD2003Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UKInt J Geriatr Psychiatry18740712891643
- WilcockGHoweIColesH2003A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s diseaseDrugs Aging207778912875613
- WilcockGKLilienfeldSGaensE2000Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study GroupBMJ3211445911110737
- WimoALjunggrenGWinbladB1997Costs of dementia and dementia care: a reviewInt J Geriatr Psychiatry12841569283930
- WimoAWinbladBEngedalK2003An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trialDement Geriatr Cogn Disord15445412457078
- WimoAWinbladBGrafstromM1999The social consequences for families with Alzheimer’s disease patients: potential impact of new drug treatmentInt J Geriatr Psychiatry143384710389036
- WimoAWinbladBStofflerA2003Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s diseasePharmacoeconomics213274012627986
- WinbladB2002Socio-economic perspectives of dementia and cost-effectiveness of treatment7th International Geneva/Springfield Symposium on Advances in Alzheimer TherapyApril 3–6Geneva, Switzerland
- WinbladBEngedalKSoininenH2001A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADNeurology574899511502918
- WinbladBPoritisN1999Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)Int J Geriatr Psychiatry141354610885864
- ZhuCMooreMClippE2003Dementia problem behavior and the production of informal caregiving servicesRev Econ Household15976